VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances

VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances Lee Rosen Oncologist 2005; 10: 382-391 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the mechanism of action of angiogenesis inhibitors currently being explored for the treatment of cancer. Compare the efficacy of standard chemotherapy alone with that of chemotherapy combined with an antiangiogenic agent for the treatment of metastatic colorectal cancer. Describe the rationale for the use of angiogenesis inhibitors in the treatment of breast cancer. Assess recent data describing the efficacy of angiogenesis inhibitors in the treatment of NSCLC. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jun. 20, 2005 Most Recent Review: Jun. 20, 2005* Most Recent Update: Jun. 20, 2005 Date Credit Expires: Jun. 20, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.